The article "Novel Therapeutic Regimens Against *Helicobacter pylori*: An Updated Systematic Review" by Ting-Ting Huang, Yong-Xiao Cao, and Lei Cao provides an comprehensive overview of the current status and challenges in treating *Helicobacter pylori* (H. pylori) infections. H. pylori is a spiral-shaped, gram-negative bacterium that causes severe gastric complications, including gastric cancer, duodenal ulcers, and gastric adenocarcinoma. Accurate diagnosis and effective treatment are crucial due to the high prevalence of the infection, which affects various regions worldwide, with rates ranging from 20% to 64%. The article reviews the evolution of H. pylori eradication treatments, from single antibiotics to combinations of multiple antibiotics, including standard triple therapies and quadruple therapies. However, increasing antimicrobial resistance has led to the development of new therapeutic regimens, such as Vono-triple therapy and R-hybrid therapy, which have shown higher eradication rates compared to traditional triple therapy. The prevalence of H. pylori infection varies across different regions, with higher rates in East Asia, Africa, and developing countries. The infection is associated with various gastrointestinal and systemic diseases, including peptic ulcers, chronic atrophic gastritis, cardiovascular diseases, neurological disorders, and metabolic disorders. The article also discusses the morphological forms of H. pylori, its virulence mechanisms, and the development of antibacterial treatments. It highlights the importance of adhesion mechanisms, inflammasomes, and virulence factors in the infection process. The effectiveness of different treatment regimens, such as high-dose dual therapy (HDDT) and bismuth quadruple therapy (BOT), is evaluated, along with the impact of patient compliance and age on treatment outcomes. The resistance of H. pylori to antibacterial drugs is a significant concern, with increasing resistance rates to clarithromycin, metronidazole, and levofloxacin. The article explores the role of biofilms and efflux pumps in drug resistance and the development of new approaches to address these challenges. These approaches include the use of natural products, probiotic interventions, vaccination, stimulus-responsive biomaterials, and phage therapy. Overall, the article emphasizes the need for innovative strategies to overcome the limitations of current treatments and improve the eradication rates of H. pylori infections.The article "Novel Therapeutic Regimens Against *Helicobacter pylori*: An Updated Systematic Review" by Ting-Ting Huang, Yong-Xiao Cao, and Lei Cao provides an comprehensive overview of the current status and challenges in treating *Helicobacter pylori* (H. pylori) infections. H. pylori is a spiral-shaped, gram-negative bacterium that causes severe gastric complications, including gastric cancer, duodenal ulcers, and gastric adenocarcinoma. Accurate diagnosis and effective treatment are crucial due to the high prevalence of the infection, which affects various regions worldwide, with rates ranging from 20% to 64%. The article reviews the evolution of H. pylori eradication treatments, from single antibiotics to combinations of multiple antibiotics, including standard triple therapies and quadruple therapies. However, increasing antimicrobial resistance has led to the development of new therapeutic regimens, such as Vono-triple therapy and R-hybrid therapy, which have shown higher eradication rates compared to traditional triple therapy. The prevalence of H. pylori infection varies across different regions, with higher rates in East Asia, Africa, and developing countries. The infection is associated with various gastrointestinal and systemic diseases, including peptic ulcers, chronic atrophic gastritis, cardiovascular diseases, neurological disorders, and metabolic disorders. The article also discusses the morphological forms of H. pylori, its virulence mechanisms, and the development of antibacterial treatments. It highlights the importance of adhesion mechanisms, inflammasomes, and virulence factors in the infection process. The effectiveness of different treatment regimens, such as high-dose dual therapy (HDDT) and bismuth quadruple therapy (BOT), is evaluated, along with the impact of patient compliance and age on treatment outcomes. The resistance of H. pylori to antibacterial drugs is a significant concern, with increasing resistance rates to clarithromycin, metronidazole, and levofloxacin. The article explores the role of biofilms and efflux pumps in drug resistance and the development of new approaches to address these challenges. These approaches include the use of natural products, probiotic interventions, vaccination, stimulus-responsive biomaterials, and phage therapy. Overall, the article emphasizes the need for innovative strategies to overcome the limitations of current treatments and improve the eradication rates of H. pylori infections.